Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in CHF (TTM)47.20bn
- Net income in CHF6.36bn
- Incorporated1996
- Employees103.00k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 6.22bn | 1.22bn | 42.60bn | 17.49k | 35.00 | 4.01 | 23.49 | 6.84 | 16.34 | 16.34 | 83.69 | 142.66 | 0.3681 | 2.28 | 5.95 | 355,722.00 | 7.20 | 5.30 | 8.63 | 6.48 | 39.18 | 39.90 | 19.57 | 15.20 | 1.27 | 21.61 | 0.1731 | 28.41 | 15.05 | 6.47 | 80.27 | 12.84 | 32.93 | 4.94 |
| Bayer AG | 49.03bn | 2.95bn | 51.90bn | 101.74k | 17.60 | 1.31 | 5.60 | 1.06 | 3.09 | 3.09 | 51.39 | 41.60 | 0.4026 | 1.67 | 3.46 | 498,071.40 | 2.44 | -1.11 | 3.30 | -1.45 | 59.54 | 58.98 | 6.05 | -3.04 | 0.7587 | 4.95 | 0.5135 | -- | 15.10 | 7.70 | 315.00 | 5.02 | 4.50 | -2.72 |
| GSK plc | 32.51bn | 4.85bn | 63.73bn | 69.40k | 12.63 | 4.82 | 8.13 | 1.96 | 1.10 | 3.64 | 7.52 | 2.89 | 0.3923 | 1.51 | 3.84 | 419,092.20 | 6.45 | 6.39 | 9.82 | 10.42 | 70.42 | 69.55 | 16.44 | 15.90 | 0.694 | 9.71 | 0.6489 | 93.37 | 18.74 | -0.5778 | 51.73 | 10.27 | 0.5035 | -5.53 |
| Sanofi SA | 44.87bn | 8.12bn | 121.86bn | 91.57k | 14.95 | -- | 11.93 | 2.72 | 6.65 | 6.65 | 36.84 | -- | -- | -- | -- | 504,504.60 | -- | 5.80 | -- | 7.02 | 69.93 | 68.49 | 18.24 | 17.00 | -- | 102.64 | -- | 59.84 | 15.86 | 4.62 | 34.52 | 17.28 | 2.39 | 3.28 |
| Novartis AG | 47.20bn | 6.36bn | 202.45bn | 103.00k | 30.22 | 3.96 | 17.72 | 4.29 | 2.94 | 2.94 | 21.78 | 22.47 | 0.4391 | 2.03 | 6.02 | 464,083.90 | 5.92 | 9.09 | 7.95 | 11.77 | 71.09 | 70.98 | 13.48 | 23.68 | 0.7931 | 12.26 | 0.3586 | 59.94 | -2.15 | 3.60 | -71.05 | -1.49 | 3.09 | 3.79 |
| AstraZeneca plc | 39.70bn | 4.26bn | 203.79bn | 83.50k | 48.14 | 6.29 | 21.68 | 5.13 | 2.44 | 2.44 | 22.77 | 18.71 | 0.4452 | 1.35 | 4.62 | 425,359.10 | 4.78 | 2.63 | 6.31 | 3.62 | 80.63 | 78.99 | 10.74 | 6.35 | 0.6959 | 6.82 | 0.468 | 187.07 | 18.53 | 14.57 | 2,835.71 | 6.63 | 9.68 | 1.13 |
| Roche Holding AG | 63.28bn | 12.42bn | 237.82bn | 103.61k | 18.93 | 8.30 | 13.69 | 3.76 | 15.36 | 15.36 | 78.32 | 35.03 | 0.7013 | 2.27 | 5.65 | 610,743.80 | 15.00 | 16.21 | 25.31 | 25.33 | 70.75 | 71.07 | 21.38 | 22.62 | 0.9256 | 19.25 | 0.4419 | 59.33 | 0.7643 | 3.49 | -10.83 | 7.26 | 2.63 | 2.74 |
| Novo Nordisk A/S | 24.55bn | 7.97bn | 254.81bn | 57.09k | 42.32 | 32.03 | 28.84 | 10.38 | 26.88 | 26.88 | 82.71 | 35.52 | 0.8422 | 1.29 | 4.34 | 3,461,659.00 | 27.34 | 29.83 | 55.67 | 58.58 | 84.22 | 83.76 | 32.47 | 32.86 | 0.6694 | 16.84 | 0.2421 | 45.88 | 25.68 | 9.64 | 16.27 | 7.81 | 11.27 | 9.57 |
Data as of May 26 2023. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF
16.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 May 2023 | 57.37m | 2.52% |
| UBS Asset Management Switzerland AGas of 31 Dec 2022 | 55.73m | 2.45% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 54.67m | 2.40% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2022 | 50.01m | 2.20% |
| Wellington Management Co. LLPas of 04 May 2023 | 44.72m | 1.96% |
| BlackRock Fund Advisorsas of 04 May 2023 | 38.55m | 1.69% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Jan 2023 | 23.08m | 1.01% |
| Dodge & Coxas of 31 Mar 2023 | 19.44m | 0.85% |
| Artisan Partners LPas of 31 Mar 2023 | 18.94m | 0.83% |
| BlackRock Advisors (UK) Ltd.as of 04 May 2023 | 18.19m | 0.80% |
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
